LCTX vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
LCTX exhibits severe financial distress as evidenced by a Piotroski F-Score of 1/9, indicating critical weakness across nearly all fundamental health dimensions. While the company maintains a strong liquidity position with a current ratio of 5.20 and low debt, it suffers from negative gross margins (-22.80%) and an unsustainable operating margin of -99.09%. The valuation is extreme, with a Price/Sales ratio of 26.70 and a PEG of 10.64, suggesting the stock is priced for perfection despite consistent earnings misses. The stark contrast between the 'Strong Buy' analyst consensus and the deterministic health scores suggests a speculative bet on clinical outcomes rather than a value-driven investment.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
LCTX vs LLY: Head-to-Head Comparison
This page compares Lineage Cell Therapeutics, Inc. (LCTX) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.